Skip to content

Depression: all studies

Page 81 of 1,034: studies 801 to 810 of 10,336, newest first. Back to the depression overview

Research

229. PSILOCYBIN WITH PSYCHOTHERAPEUTIC SUPPORT FOR TREATMENT-RESISTANT DEPRESSION: A PILOT CLINICAL TRIAL

The International Journal of Neuropsychopharmacology August 1, 2025 Susan Meikle, Olivia Carter, Paul Liknaitzky et al.

Abstract Background Depressive disorders are a major global health challenge, with many individuals unresponsive to existing treatments or left with residual symptoms such as impairments in cognition and social functioning. Emerging psychedelic therapies show promise for treating depression but require further research. Aims & Objectives This pilot study aimed to evaluate the feasibility,...

The Impact of Online Mindfulness Interventions on Postpartum Depression: A Systematic Review and Meta-Analysis.

International Journal of Mental Health Nursing August 1, 2025 Qier Liu, Jiaqi Yuan, Siyao Shi et al.

Postpartum depression is a significant global public health issue, with serious maternal and neonatal consequences. Online mindfulness interventions provide a promising alternative, offering flexible and low-risk support that overcomes barriers like stigma and accessibility. This review aimed to assess the effects of online mindfulness interventions on postpartum depression, anxiety, and stress...

DOI: 10.1111/inm.70085 (opens in new tab) Full text (opens in new tab) Mindfulness Mhealth Postpartum depression Postpartum health +1

The Effects of Ketamine and Esketamine on Measures of Quality of Life in Major Depressive Disorder and Treatment-Resistant Depression: A Systematic Review.

Journal of Affective Disorders August 1, 2025 Morgan C H Cheng, Christine E. Dri, Hana Ballum et al. 12 citations

The rapid and clinically meaningful antidepressant effects of ketamine and esketamine are well-established in major depressive disorder (MDD) and treatment-resistant depression (TRD) as evidenced by improvement in clinician- and patient-reported depression measures. However, there remains a need to determine how these agents affect patient-reported quality of life (QoL). Herein, we aimed to...

DOI: 10.1016/j.jad.2025.04.119 (opens in new tab) Full text (opens in new tab) Esketamine Patient-reported outcomes Quality of life Depression therapy +4

Effect of ketamine and esketamine on RNA expression and its relevance for depression: a systematic review.

Pharmacological Research July 31, 2025 C. Pisanu, R. Carvalho Silva, Mattia Meattini et al. 6 citations

Treatment-resistant depression (TRD) remains a challenge in psychiatry, necessitating novel therapeutic strategies beyond traditional monoaminergic antidepressants. Ketamine and its S-enantiomer esketamine have demonstrated rapid and robust antidepressant effects in TRD, probably through mechanisms involving glutamatergic modulation, neuroplasticity, and anti-inflammatory properties. However,...

An Integrated Mindfulness Intervention For Emotional Numbness In Major Depression: A Case Study

Seurune: Jurnal Psikologi Unsyiah July 30, 2025 Adelina Rahmawati

This single-case study aims to examine the effectiveness of an integrated mindfulness-based intervention in reducing symptoms of emotional numbness in major depressive disorder. A 30 year old female participant with severe depression (BDI-II = 29) received 12 individual sessions combining mindfulness-based cognitive therapy, body-centered mindfulness, and compassion-focused therapy at a private...

Novel Non-hallucinogenic Neurite Growth Compounds as 5‑HT2A Agonists for Treating Stress-Related Disorders, Namely Depression, Anxiety, and PTSD.

ACS Medicinal Chemistry Letters July 30, 2025

Provided herein are novel non-hallucinogenic neurite growth compounds as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating stress-related disorders, namely depression, anxiety, and post-traumatic stress disorder (PTSD), and processes for preparing such compounds.

Long-Term Outcomes in Patients with Treatment-Refractory Depression Receiving Intravenous Ketamine and Intranasal Esketamine: An Observational Study

The Journal of Clinical Psychiatry July 30, 2025 Balwinder Singh, Vanessa K. Pazdernik, Simon Kung et al.

Objective: This study examines the durability (defined as time between treatments) of intravenous ketamine (IV-KET) and intranasal esketamine (IN-ESKET) for treatment-resistant depression (TRD), in a real-world clinical setting with repeated ketamine/esketamine maintenance therapy. Methods: This was a single-center, observational study of adults with TRD who completed acute-phase treatment...

Psilocybin-assisted treatment of depression

Medical Science July 30, 2025 Barbara Anna Zapalska, Antonina Teresa Witkowska, Anna Cukrowska et al.

Depression, a common mental disorder, affects people at different stages of life.Classic antidepressant treatment is generally effective, however, it is prolonged.Nonetheless, numerous patients who undergo various classic antidepressant therapies still suffer from depression.Therefore, the search for novel medications is essential.In this review, we explore the therapeutic potential of...

Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression

JAMA Network Open July 30, 2025 Fredrik Hieronymus, Evana López, Helena Werin Sjögren et al. 21 citations

Importance Psilocybin has demonstrated rapid and sustained antidepressant efficacy, with acute-phase effect sizes often more than double those for conventional antidepressants. However, concerns have been raised that high rates of functional unblinding in combination with trial participants with positive expectations of psychedelic use might bias treatment outcomes. Objective To compare...

DOI: 10.1001/jamanetworkopen.2025.24119 (opens in new tab) Full text (opens in new tab) Psilocybin trials Psilocybin research Psychedelic studies Depression drug trials +13

Death recollection moderates stress-influenced depression in Thai boarding school students.

BMC Psychology July 29, 2025 Justin DeMaranville, Tinakon Wongpakaran, Nahathai Wongpakaran et al. 2 citations

Death recollection is a form of mindfulness meditation that orients a practitioner's calm attention toward an awareness of death. This meditation is practiced by Theravada Buddhists of all ages throughout Thailand. This research investigates how recollecting death influences Thai teenager mental health. Purposive and convenience sampling methods were used to recruit participants from five...